Amanda L. Olson, M.D.

Peer-Reviewed Articles

1. Saengboon S, Ciurea S, Popat U, Ramdial J, Bashir Q, Alousi A, Chen J, Rondon G, Olson A, Im J, Hosing C, Shpall E, Champlin R, Srour SA. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv 8(12):3237-3245, 2024. PMID: 38607399.
2. Rischall, A, Olson, AL. SOHO State of the Art Updates and Next Questions | CTLs for Infections Following Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia 24(6):340-347, 2024. PMID: 38267354.
3. Khouri, IF, Alzahrani, K, Kantarjian, HM, Milton, D, Gulbis, A, Sasaki, K, Jain, N, Short, NJ, Kadia, TM, Daher, M, Rafei, H, Im, JS, Marin, D, Olson, AL, Popat, UR, Qazilbash, MH, Ramdial, JL, Rondon, G, Srour, S, Kebriaei, P, Shpall, E, Champlin, RE, Jabbour, EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. American journal of hematology 99(5):836-843, 2024. PMID: 38400519.
4. Ahmed, S, Bashir, Q, Bassett Jr, R, Ullah, F, Aung, FM, Valdez, B, Alousi, AM, Hosing, C, Kebriaei, P, Khouri, IF, Marin, D, Nieto, Y, Olson, AL, Oran, B, Qazilbash, MH, Rezvani, K, Mehta, RS, Shpall, E, Ciurea, SO, Andersson, BS, Champlin, RE, Popat, UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. American journal of hematology 99(4):562-569, 2024. PMID: 38314663.
5. Marcoux, C, Saliba, RM, Wallis, W, Khazal, SJ, Ragoonanan, D, Rondon, G, Tewari, P, Popat, UR, Oran, B, Olson, AL, Bashir, Q, Qazilbash, MH, Alousi, AM, Hosing, C, Nieto, Y, Al-Atrash, G, Marin, D, Rezvani, K, Khouri, IF, Srour, S, Champlin, RE, Shpall, E, Kebriaei, P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Advances 8(5):1128-1136, 2024. PMID: 38266155.
6. Joseph, JJ, Srour, S, Milton, D, Ramdial, JL, Saini, N, Olson, AL, Bashir, Q, Oran, B, Alousi, AM, Hosing, C, Qazilbash, MH, Kebriaei, P, Shpall, E, Champlin, RE, Popat, UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and Cellular Therapy 29(12):770.e1-770.e6, 2023. PMID: 37742746.
7. Tanco K, Olson A, Fellman B, Jankowski M, Lai SY, Shete S, Harbison K, Scheid J, Bruera E. Analysis of Dispensing and Utilization Patterns of Medical Cannabis Products in State Licensed Cannabis Dispensaries. Journal of palliative medicine 26(11):1482-1487, 2023. PMID: 37285183.
8. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Advances 7(20):6196-6205, 2023. PMID: 37611156.
9. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
10. Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematologic Stem-Cell Transplant. JCO Oncol Pract 19(3):OP2200520, 2023. e-Pub 2023. PMID: 36626702.
11. Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, Olson A. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med 12(2):55-71, 2023. e-Pub 2023. PMID: 36779789.
12. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2022. PMID: 36502492.
13. Saengboon, S, Ramdial, JL, Saini, N, Olson, AL, Im, J, Hosing, C, Popat, UR, Shpall, E, Champlin, RE, Srour, S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clinical Lymphoma, Myeloma and Leukemia 22:S259-S260, 2022. PMID: 36163857.
14. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study. Haematologica 107(10):2496-2500, 2022. e-Pub 2022. PMID: 35770531.
15. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
16. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
17. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
18. Gaballa MR, Banerjee P, Milton DR, Jiang X, Ganesh C, Khazal S, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta R, Alatrash G, Khouri I, Oran B, Marin D, Popat U, Olson A, Tewari P, Jain N, Jabbour E, Ravandi F, Kantarjian H, Chen K, Champlin R, Shpall E, Rezvani K, Kebriaei P. Blinatumomab Maintenance After Allogeneic Hematopoietic Cell Transplantation for B-lineage Acute Lymphoblastic Leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2021. PMID: 34914826.
19. Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13:1032397, 2022. e-Pub 2022. PMID: 36439104.
20. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia 36(1):155-164, 2022. e-Pub 2021. PMID: 34312462.
21. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2021. PMID: 34629467.
22. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
23. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
24. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
25. Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
26. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):JCO2002608, 2021. e-Pub 2021. PMID: 33929874.
27. Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
28. Tong Y, Florjancic AS, Clark RF, Lai C, Mastracchio A, Zhu GD, Smith ML, Kovar PJ, Shaw B, Albert DH, Qiu W, Longenecker KL, Liu X, Olson AM, Osterling DJ, Tahir SK, Phillips DC, Leverson JD, Souers AJ, Penning TD. Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. ACS Med Chem Lett 12(7):1108-1115, 2021. e-Pub 2021. PMID: 34267880.
29. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(7):1746-1749, 2021. e-Pub 2021. PMID: 33767403.
30. Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat UR. Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica 106(7):1988-1990, 2021. e-Pub 2021. PMID: 31296578.
31. Shah MV, Saliba RM, Varma A, Ciurea SO, Oran B, Olson A, Bose P, Bashir Q, Masarova L, Alousi AM, Srour S, Mehta RS, Daver N, Pemmaraju N, Verstovsek S, Champlin RE, Popat UR. Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era. Br J Haematol 193(5):1004-1008, 2021. e-Pub 2021. PMID: 33821472.
32. Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
33. Olson AL, Politikos I, Brunstein C, Milano F, Barker J, Hill JA, Interest Group ASFTACTCBS. Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation. Transplant Cell Ther 27(5):359-362, 2021. PMID: 33965172.
34. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
35. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients. medRxiv None(None):None, 2021. e-Pub 2021. PMID: 33758890.
36. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2020. PMID: 33781539.
37. Kim, P, Masha, L, Olson, AL, Iliescu, C, Karimzad, K, Hassan, SA, Palaskas, NL, Durand, J, Leung, CH, Lopez-Mattei, J. QT Prolongation in Cancer Patients. Frontiers in Cardiovascular Medicine 8, 2021. PMID: 33718445.
38. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 3(2):74-81, 2021. e-Pub 2020. PMID: 32604096.
39. Greenbaum U, Klein K, Martinez F, Song J, Thall PF, Ramdial JL, Knape C, Aung FM, Scroggins J, Knopfelmacher A, Mulanovich V, Borjan J, Adachi J, Muthu M, Leung C, Medina MC, Champlin R, Olson A, Alousi A, Rezvani K, Shpall EJ. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Front Immunol 12:675679, 2021. e-Pub 2021. PMID: 33995420.
40. Heinle L, Sulaiman K, Olson A, Ruterbories K. A homologous series of internal standards for near universal application in the discovery LC-MS/MS bioanalytical laboratory. J Pharm Biomed Anal 190(None):113578, 2020. e-Pub 2020. PMID: 32877849.
41. Greenbaum U, Ramdial JL, Olson A, Nieto Y, Strati P, Ahmed S, Neelapu SS, Tummala S, Chi L, Shpall EJ, Kebriaei P. Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T-cell therapy: a case report and brief review of the literature. Adv Cell Gene Ther None(None):None. e-Pub 2020. PMID: None.
42. Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in Allogeneic Stem cell Transplant Recipients. Transpl Infect Dis 22(5):e13395, 2020. e-Pub 2020. PMID: 32602954.
43. Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Graft Failure After the First Allograft. Am J Hematol 95(10):E267-E269, 2020. e-Pub 2020. PMID: 32602112.
44. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
45. Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood 135(6):449-452, 2020. PMID: 31826244.
46. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
47. Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
48. Ciurea SO, Varma A, Kongtim P, Srour S, Bashir Q, Alousi AM, Mehta RS, Oran B, Popat U, Hosing C, Rondon G, Chen J, Olson AL, Konopleva MY, Champlin RE. Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis. Blood 134(Supplement_1):42, 2019. PMID: 31724003.
49. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
50. Chamoun K, Milton DR, Ledesma C, Young KH, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Marin D, Molldrem JJ, Olson AL, Oran B, Popat UR, Rondon G, Champlin RE, Gulbis AM, Khouri IF. Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant 25(7):1347-1354, 2019. e-Pub 2019. PMID: 30826465.
51. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget 9(86):35611-35622, 2018. e-Pub 2018. PMID: 30479692.
52. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. PMID: 30389035.
53. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379(15):1443-1451, 2018. PMID: 30304652.
54. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of non-permissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
55. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2017. PMID: 29269797.
56. Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 9(OCT):2444, 2018. e-Pub 2018. PMID: 30405633.
57. Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson AL, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
58. Khan M, Adil SE, Olson AL. The role of mesenchymal stem cells in oncology and regenerative medicine. Future Oncol 13(9):821-831, 2017. e-Pub 2016. PMID: 27908206.
59. Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson AL, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2016. PMID: 27862740.
60. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2016. PMID: 27816651.
61. Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, Marin D, Olson AL, Patel KK, Popat UR, Ledesma C, Kadia TM, Ferrajoli A, Burger JA, Jorgensen JL, Medeiros LJ, Bassett RL, Gulbis AM. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant 52(1):28-33, 2017. e-Pub 2016. PMID: 27595282.
62. Khan M, Mansoor AE, Olson AL. Prospects of chimeric antigen receptor T-cell and natural killer cell therapies in acute leukemias. Future Oncol 12(19):2179-82, 2016. e-Pub 2016. PMID: 27250512.
63. Sarvaria A, Basar R, Mehta RS, Shaim H, Muftuoglu M, Khoder A, Sekine T, Gokdemir E, Kondo K, Marin D, Daher M, Alousi AM, Alsuliman A, Liu E, Oran B, Olson AL, Jones RB, Popat U, Hosing C, Champlin R, Shpall EJ, Rezvani K. IL-10+ regulatory B cells are enriched in cord blood and may play a role in protection against GVHD after cord blood transplantation. Blood 128(10):1346-61, 2016. e-Pub 2016. PMID: 27439912.
64. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson AL, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
65. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson AL, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing C. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1607-15, 2016. e-Pub 2015. PMID: 26472485.
66. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant 51(7):999-1001, 2016. e-Pub 2016. PMID: 26950376.
67. Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Osama Gaber A, Salahudeen A, Oran B, Chemaly RF, Olson AL, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2015. PMID: 26608093.
68. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson AL, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better Allele-level Matching Improves Transplant Related Mortality after Double Cord Blood Transplantation. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
69. Saliba RM, Rezvani K, Leen A, Jorgensen J, Shah N, Hosing C, Parmar S, Oran B, Olson AL, Mehta RS, Chemaly R, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution Following Double Cord Blood Transplantation. Biol Blood Marrow Transplant 21(7):1284-90, 2015. e-Pub 2015. PMID: 25708219.
70. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. PMID: 26039209.
71. Dahi PB, Perales MA, Devlin SM, Olson AL, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Papanicolaou G, Barker JN. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leuk Lymphoma 56(6):1-7, 2015. e-Pub 2014. PMID: 25224458.
72. Olson AL, McNiece IK. Novel clinical uses for cord blood derived mesenchymal stromal cells. Cytotherapy 17(6):796-802, 2015. e-Pub 2015. PMID: 25819838.
73. Popat, UR, Mehta, RS, Rezvani, K, Fox, PS, Kondo, K, Marin, D, McNiece, I, Oran, B, Hosing, C, Olson, AL, Parmar, S, Shah, ND, Andreeff, M, Kebriaei, P, Kaur, I, Yvon, ES, De Lima, M, Cooper, L, Tewari, P, Champlin, RE, Nieto, Y, Andersson, BS, Alousi, AM, Jones, R, Qazilbash, MH, Bashir, Q, Ciurea, SO, Ahmed, S, Anderlini, P, Bosque, DM, Bollard, CM, Molldrem, JJ, Chen, J, Rondon, G, Thomas, MW, Miller, LP, Wolpe, S, Simmons, PJ, Robinson, SN, Zweidler-McKay, PA, Shpall, E. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-2892, 2015. PMID: 25778529.
74. Munoz J, Shah N, Rezvani K, Hosing C, Bollard CM, Oran B, Olson AL, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present, and future. Stem Cells Transl Med 3(12):1435-43, 2014. e-Pub 2014. PMID: 25378655.
75. Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, Perales MA, Papadopoulos EB, Ponce DM, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, Papanicolaou G, Barker JN. Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. Biol Blood Marrow Transplant 20(6):787-93, 2014. e-Pub 2014. PMID: 24548875.
76. Cook MR, Shouval R, Perales M, Bezerra E, Niu A, Dahiya S, Nastoupil LJ, Jacobson CA, L Elizabeth Budde L, Olson AL, Logan BR, Hu Z, Wang H, Luo Z, Kim JJ, Smith HW, Lee A, Sun F, Pasquini M, Locke FL. Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL). Blood 142(Supplement 1):103. PMID: None.

Other Articles

1. Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. PMID: None.
2. Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol 87(6):2414-2424, 2021. PMID: 32463929.
3. Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. PMID: 32623078.
4. Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, Horwitz M, Milano F, Olson AL, Spellman S, Wagner JE, Delaney C, Shpall E Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant 23(6):882-896, 2017. PMID: 28279825.
5. Mehta RS, Rezvani K, Olson AL, Oran B, Hosing C, Shah N, Parmar S, Armitage S, Shpall EJ Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. Front Med (Lausanne) 2(None):89, 2015. PMID: 26697430.
6. Smallbone P, Fingrut BW, Olson AL MSCs in Hematology. Best Practice & Research Clinical Haematology None(None):None. PMID: None.

Abstracts

1. Velarde AM, Saliba RM, Ledesma C, Shpall EJ, Qazilbash MH, Popat UR, Bashir Q, Nieto Y, Marin D, Oran B, Olson AL, Srour SA, Alousi A, Ramdial J, Kebriaei P, Ferrajoli A, Wierda WG, Champlin RE, Hosing C. Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis. Blood 142(Supplement 1):None, 2023. PMID: None.
2. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood 142(Supplement 1):4972-4974, 2023. PMID: None.
3. Khouri F, Kamal A, Alison G, Koji S, Nitin J, Short Nicholas J, Kadia Tapan M, May D, Hind R, Im Jin S, David M, Olson Amanda L, Popat Uday R, Qazilbash Muzaffar H, Jeremy R, Gabriela R, Srour Samer A, Partow K, Shpall Elizabeth J, Kantarjian Hagop M, Champlin Richard E, Elias J. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results. Blood 142(Supplement 1):233-235, 2023. PMID: None.
4. Jadhav S, Shaerma NK, Mallaiah SG, Rwezy S, Rao R, Truong MP, Ochoa JM, Olson AL, Daher M, Majumdar V. Cultural Tailoring of an Inpatient Yoga Program for Cancer Patients Undergoing Stem Cell Transplantation in Tanzania, India and United States. None None(None):None, 2023. PMID: None.
5. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi AM, Olson AL, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin RE, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. Blood 140(Supplement 1):7695-7698, 2022. PMID: None.
6. Khouri IF, Hwang H, Neelapu SS, Wang X, Hosing CM, Ahmed S, Kebriaei P, Daher M, Olson AL, Anderlini P, Im JS, Westin J, Shpall EJ, Champlin RE, Nastoupil LJ. Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30. Blood 140(Supplement 1):7502-7503, 2022. PMID: None.
7. Greenbaum U, Hashmi H, Elsawy M, Kim S, Moskop A, Awan FT, Farooq U, Ganguly S, Hematti P, Jain MD, Kebriaei P, Locke FL, Mead E, Nishihori T, Olson AL, Pennisi M, Perales MA, Geethakumani PR, Shouval R, Shpall EJ, Magalhaes-Silverman M, Strouse C, Turtle CJ, Vallurupalli A, Wudhikam K, Pasquini MC, Ahmed S, Sorror M. Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART). Blood 140(Supplement 1):4636-4638, 2022. PMID: None.
8. Bansil S, Motta C, Dicioccio R, O'Brien S, Lang H, Keller M, Abraham A, Jacobson D, Davila Saldana BJ, Olson AL, Shpall EJ, Kaur I, Hanley PJ, Bollard CM. Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells. Blood 140(Supplement 1):10239-10240, 2022. PMID: None.
9. Cox N, Saengboon S, Olson AL, Qazilbash MH, Shpall EJ, Champlin RE, Srour SA. Impact of Vitamin D Deficiency on Survival for Patients Received Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT). Blood 138(Supplement 1):4853, 2021. PMID: None.
10. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 138(Supplement 1):556, 2021. PMID: None.
11. Popat UR, Mehta RS, Bassett R, M Alousi AA, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 138(Supplement 1):1802, 2021. PMID: None.
12. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood 138(Supplement 1):1803, 2021. PMID: None.
13. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 138(Supplement 1):2879, 2021. PMID: None.
14. Oran B, Alousi AM, Mehta RS, Marin D, Kebriaei P, Popat UR, Olson AL, McCarty JM, Ramos JD, Bassett R, Keer HN, Thall PF, Champlin RE. Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. Blood 136(Supplement 1):10-11, 2020. PMID: None.
15. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, lyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. Blood 136(Supplement 1):None, 2020. PMID: None.
16. Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma C, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax-Based Therapy. Blood 136(Supplement 1):None, 2020. PMID: None.
17. Joseph J, Milton DR, Chen J, Alatrash G, Alousi AM, Bashir Q, Ciurea SO, Daher M, Im JS, Mehta RS, Oran B, Olson AL, Saini N, Srour SA, Andersson BS, Champlin RE, Popat UR. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. Journal of Clinical Oncology 38(15):e19520, 2020. PMID: None.
18. Mukherjee A, Milton DR, Gulbis A, Ledesma C, Jabbour E, Alousi AM, Bashir Q, Daher M, Oran B, Olson AL, Marin D, Srour S, Kebriaei P, Mehta RS, Nemeth KP, Popat U, Im JS, Champlin RE, Khouri IF. Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Donor (MUD) Transplantation in Patients (pts) with Relapsed/Refractory Lymphoma. Blood 134(Supplement 1):4530, 2019. PMID: None.
19. Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 134(Supplement 1):3296, 2019. PMID: None.
20. Yalniz FF, Saliba RM, Yucel OK, Garcia-Manero G, Ramdial J, Popat U, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Hosing C, Marin D, Mehta R, Olson AL, Rezvani K, Shpall EJ, Rondon G, Champlin RE, Oran B. Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation. Blood 134(Supplement 1):512, 2019. PMID: None.
21. Ciurea SO, Bassett R, Soebbing D, Rondon G, Cao K, Olson AL, Bashir Q, Shpall EJ, Devine S, Pasquini MC, Martin AS, Lee AD, Champlin RE. Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls. Blood 134(Supplement 1):700, 2019. PMID: None.
22. Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 134(Supplement 1):256, 2019. PMID: None.
23. Wang Y, Young KH, Milton DR, Ledesma C, Jabbour E, Xu-Monette ZY, Molldrem JJ, Anderlini P, Alousi AM, Bashir Q, Daher M, Fayad LE, lyer SP, Kebriaei P, Marin D, Mehta RS, Olson AL, Popat U, Samaniego F, Westin JR, Qazilbash MH, Im JS, Rondon G, Gulbis A, Champlin RE, Khouri IF. Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation. Blood 134(Supplement 1):None, 2019. PMID: None.
24. Zeng K, Ma H, Popat U, Nieto Y, Ciurea SO, Olson AL, Lyu M, Huang M, Nishimoto M, Qazilbash MH, Ramos JD, Shpall EJ, Champlin RE, Parmar S, Andersson BS. Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial. Blood 134(Supplement 1):4547, 2019. PMID: None.
25. Champlin RE, Popat U, Oran B, Ciurea SO, Kebriaei P, Alousi AM, Alatrash G, Bashir Q, Khouri IF, Hosing C, Anderlini P, Jones RB, Marin D, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Shpall EJ, Chen J, Rondon G, McMullin B, Al Jahdhami VP, Kawedia J, Valdez BC, Ma J, Thall PF, Andersson BS. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood 134(Supplement 1):257, 2019. PMID: None.
26. Khouri IF, Milton DR, Ledesma C, Nastoupil LJ, Jabbour E, Anderlini P, Bashir Q, O Curea CS, May D, Fayad Luis E, Im Jin S, Iyer Swaminathan P, David M, Mehta Rohtesh S, Molldrem Jeffrey J, Olson Amanda L, Betul O, Uday P, Muzaffar Q, Samer S, Felipe S, Gabriela R, Jeffrey ML, Alison G, Champlin Richard E. Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantation (ASCT) for Patients (pts) with Relapsed Follicular Lymphoma (FL). Blood 134(Supplememt 1):322, 2019. PMID: None.
27. Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi AM, Mehta RS, Oran B, Olson AL, Hosing C, Qazilbash MH, Khouri IF, Ciurea SO, Shpall EJ, Jorgensen JL, Wang SA, Jain N, Jabbour E, Kantarjian HM, Champlin RE, Konopleva MY, Kebriaei P. Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood 134(Supplement 1):4598, 2019. PMID: None.
28. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. Journal of Clinical Oncology 37(15):None, 2019. PMID: None.
29. Rafei H, Imahashi N, Basar R, Banerjee PP, Daher M, Ganesh C, Hosing C, Kaur I, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Spencer BP, Srour S, Shpall EJ, Champlin RE, Marin D, Rezvani K. Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. Journal of Clinical Oncology 37(15):None, 2019. PMID: None.
30. Ciurea SO, Saliba R, Soebbing D, Rondon G, Cao K, Ahmed S, Olson AL, Bashir Q, Kaur I, Shpall EJ, Lee DA, Champlin RE. Enhanced antitumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation. Journal of Clinical Oncology 37(8):None, 2019. PMID: None.
31. Popat U, Mehta RS, Bassett Jr RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. Blood 132(Supplement 1):3373, 2018. PMID: None.
32. Khouri IF, Milton DR, Ledesma C, Jabbour EJ, Alatrash G, Anderlini P, Alousi AM, Bashir Q, Ciurea SO, Hymes S, Marin D, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Gulbis A. Influence of the Intensity of the Conditioning Regimens on the Risks of Gvhd in Patients Receiving Rituximab Prophylaxis during Allogeneic Stem Cell Transplantation (alloSCT). None 132(Supplement 1):4584, 2018. PMID: None.
33. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran E, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister F, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. Blood 132(Supplement 1):3356, 2018. PMID: None.
34. Oran B, Ciurea SO, Marin D, McCarty J, Bashir Q, Ahmed S, Olson AL, Popat U, Nieto Y, Kebriaei P, Shpall EJ, Agrawal T, Champlin RE. Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. Blood 132(Supplement 1):3426, 2018. PMID: None.
35. Khouri IF, Milton DR, Ledesma C, Erwin WD, Jabbour EJ, Alatrash G, Anderlini P, Bashir Q, Ciurea SO, Im JS, Marin D, Mehta RS, Molldrem JJ, Olson AL, Oran B, Popat U, Qazilbash MH, Rondon G, Champlin RE, Medeiros JL, Gulbis A. Durability Results of Non-Myeloablative (NMA) Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed Follicular Lymphoma: 17-Year Experience. Blood 132(Supplement 1):4651, 2018. PMID: None.
36. Kellner J, Yvon E, Khoury K, Tuongvan N, Ramos J, Olson AL, Nieto Y, Ciurea, SO, Nierkens S, Delemarre E, Boelens JJ, Champlin RE, Andersson BS, Parmar S. Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease. Journal of Clinical Oncology 36(15):e15047, 2018. e-Pub 2018. PMID: None.
37. Abudayyeh A, Abdelrahim M, Lin HY, Page VD, Rondon G, Andersson B, Martinez C, Tarrand J, Kontoyiannis DP, Marin D, Gaber A, Oran B, Chemaly R, Olson AL, Jones RB, Popat UR, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for symptomatic BKV infection. Journal of Clinical Oncology 36(15):7057, 2018. PMID: None.
38. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. Blood 130(Supplement 1):3267, 2017. PMID: None.
39. Ciurea SO, Saliba RM, Chen J, Rondon G, Popat U, Parmar S, Anderson B, Alousi AM, Ahmed S, Bashir Q, Alatrash G, Hosing C, Olson AL, Mehta RS, Rezvani K, Shpall EJ, Khouri IF, Kebriaei P, Champlin RE. Allogeneic Transplantation for TP53+AML: Prognostic Factors for Survival. Blood 130(Supplement 1):1938, 2017. PMID: None.
40. Kellner J, Ciurea SO, Olson AL, Nieto Y, Andersson BS, Khoury JD, Champlin RE, Nierkens S, Boelens JJ, Blazar B, Parmar S. Cord Blood Regulatory T Cells for Prevention of Graft Versus Host Disease. Blood 130(Supplement 1):3246, 2017. PMID: None.
41. Popat UR, Saliba R, Oran B, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Qazilbash MH, Rezvani K, Valdez B, Jones RB, Shpall EJ, Andersson B, Champlin RE. Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS. Journal of Clinical Oncology 35(15):7046, 2017. PMID: None.
42. Abudayyeh A, Lin HY, Abdelrahim M, Rondon G, Andersson B, Martinez C, Tarrand J, Chemaly R, Kontoyiannis DP, Marin D, Olson AL, Champlin RE, Shpall EJ, Rezvani K. A validated symptomatic BKV risk assessment score in patient post allogeneic stem cell transplant. Journal of Clinical Oncology 35(15):e18536, 2017. PMID: None.
43. Oran B, Muftuoglu M, Kaur I, Li L, Yvon E, Abueg G, Bassett R, Thall PF, Marin D, Alousi AM, Ahmed S, Ciurea SO, Nina S, Hosing C, Olson AL, Parmar S, Jones R, Popat UR, Andersson BS, Champlin RE, Shpall EJ, Rezvani K. Most Closely HLA-Matched Third Party Allogeneic CMV Specific T-Cells Generated Using the Cytokine Capture System for the Treatment of CMV Infections after Allogeneic Stem Cell Transplantation. Blood 128(22):4547, 2016. PMID: None.
44. Kebriaei P, Wei W, Thall PF, Ledesma C, Valdez BC, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Marin D, Rezvani K, Nieto Y, Champlin RE, Andersson BS. Busulfan (Bu) in Combination with Double Nucleoside Analogues Fludarabine (Flu) and Clofarabine (Clo) Plus Vorinostat As a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Blood 128(22):64, 2016. PMID: None.
45. Cerrada SL, Marin D, Rondon G, Ledesma C, Popat UR, Olson AL, Alousi AM, Oran B, Ahmed S, Ciurea SO, Patel K, Shpall EJ, Hosing C, Qazilbash MH, Shah N, Rezvani K, Jabbour E, Kantarjian HM, Champlin RE, Kebriaei P. Impact of New Anti-Leukemia Agents on Transplant Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) in Second Complete Remission. Blood 128(22):4676, 2016. PMID: None.
46. Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Khouri IF, Nieto Y, Popat UR, Marin D, Rezvani K, Kebriaei P, Shah N, Olson AL, Shpall EJ, Champlin RE, Oran B. Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood 128(22):2276, 2016. PMID: None.
47. Olson AL, Muftuoglu M, Kaur I, Li L, Abueg G, Chemaly R, Yvon E, Thall P, Marin D, Alousi A, Ahmed A, Ciurea S, Hosing C, Kebriaei P, Jones R, Andersson B, Shah N, Oran B, Abudayyeh A, Popat U, Champlin R, Shpall EJ, Rezvani K. Efficacy of Third Party BK Virus (BKV) Specific Cytotoxic T-Lymphocytes Generated By Ex Vivo Expansion for the Treatment of BKV Infection in Stem Cell Transplant Recipients, a Phase 2 Trial. American Society of Hematology None(504):None, 2016. PMID: None.
48. Popat UR, Ray G, Bassett Jr RL, Poon MC, Valdez BC, Konoplev S, Ahmed S, Alousi AM, Andersson B, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Kim S, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin RE. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. Blood 126(23):None, 2015. PMID: None.
49. Kebriaei P, Basset RL, Jr, Ledesma C, Rondon G, Oran B, Ciurea SD, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Blood 126(23):None, 2015. PMID: None.
50. Abudayyeh A, Hamdi A, Lin HY, Abdelrahim M, Rondon, Rondon G, Kontoyiannis DP, Olson AL, Andersson B, Champlin RE, Shpall EJ, Rezvani K. Symptomatic BK virus as a significant independent predictor of immune suppression and poor overall survival in allogeneic hematopoietic stem cell recipients. Journal of Clinical Oncology 33(15):7025, 2015. PMID: None.
51. Baljevic M, Cao K, Champlin RE, Hosing C, Shah N, Parmar S, Rezvani K, Olson AL, Shpall EJ, Oran B. Use of dual donor T-cell chimerism to predict prognosis after double cord blood allogeneic transplantation. Journal of Clinical Oncology 33(15):None, 2015. PMID: None.
52. Olson AL, Saliba R, Oran B, Chen J, Alousi A, Ahmad S, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Parmar S, Shah N, Shpall EJ, Qazilbash M, Andersson B, Champlin R, Popat U. Cytogenetics and Blast Count Determine Outcomes Advanced AML. Biology of Blood and Marrow Transplantation None(None):None, 2015. PMID: None.
53. Oran B, Cao K, Saliba R, Hosing C, Popat U, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson AL, Moore B, Champlin R, Rezvani K, Shpall E. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. American Soiety of Hematology None(None):None, 2014. PMID: None.
54. Popat U, Patricia F, Bassett R, Chen J, Valdez B, Kawedia J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash M, Shah N, Shpall E, Andersson B, Champlin R. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. American Society of Hematology None(None):None, 2014. PMID: None.
55. Ahmed S, Shpall E, Gulbis A, Jones R, Martinez C, Rondon G, Rezvani K, Oran B, Olson AL, Shah N, Parmar S, Popat U, Alousi A, Nieto Y, Hosing C, Bashir Q, Kebriaei P, Qazilbash M, Champlin R, Mulanovich V. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. American Society of Hematology None(None):None, 2014. PMID: None.
56. Olson AL, Lehrman R, Devlin S, Maloy M, Malaspina-Castro H, Giralt SA, Goldberg J, O'Reilly R, Perales M, Papadopoulos E, Jakubowski AA. The Prognostic Significance of Peripheral Blood Mixed Chimerism After T-Cell Depleted Allogeneic Stem Cell Transplant. Biology of Blood and Marrow Transplantation 19(2):s301-s302, 2013. PMID: None.
57. Dahi P, Olson AL, Devlin S, Lubin M, Gonzales AM, Evans K, Scaradavou A, Kernan N, Small T, O'Reilly R, Giralt SA, Koehne G, Perales M, Ponce D, Papanicolaou Z, Barker JN. Incidence, Nature, Risk Factors and Outcomes of Cytomegalovirus Infection After Double-Unit Cord Blood Transplantation. Biology of Blood and Marrow Transplantation 19(2):s344-s345, 2013. PMID: None.
58. Olson AL, Dahi P, Zheng J, Devlin S, Lubin M, Gonzales AM, Giralt SA, Ponce D, Kernan N, Scaradavou A, Papanicolaou G, Barker JN. Human Herpesvirus-6 (HHV-6) Viremia Is Frequent but the Incidence of Encephalitis Is Low in Double-Unit Cord Blood Transplantation (CBT) Recipients Transplanted without ATG By. Biology of Blood and Marrow Transplantation 19(2):s125-s125, 2013. PMID: None.
59. Olson AL, Barker JN, Castro-Malaspina H, Devlin S, Giralt SA, Goldberg JD, Lehrman R, Maloy M, O'Reilly RJ, Perales M, Papadopoulos EB, Jakubowski AA. Bone Marrow Mixed Chimerism Is a Risk Factor for Relapse After T-Cell Depleted Allogeneic Stem Cell Transplant. Blood 120(21):None, 2012. e-Pub 2012. PMID: None.
60. Olson AL, Dahi PB, Zheng J, Devlin S, Lubin MN, Gonzales AM, Giralt SA, Ponce DM, Kernan NA, Scaradavou A, Papanicolaou G, Barker JN. HHV-6 Viremia Is Frequent but the Incidence of Encephalitis Is Low in Double-Unit Cord Blood Transplant Recipients Transplanted without ATG. Bloood 120(21):459, 2012. PMID: None.
61. Olson A, Bevers T, Guzman M, Theriault R, Hortobagyi G, Hahn K. Cervical and colorectal cancer screening among breast cancer (BrCa) survivors followed in either a breast center (BC) or a breast survivorship clinic (SvC) at The University of Texas MD Anderson Cancer Center. Journal of Clinical Oncology 27(15):e20506, 2009. PMID: None.
62. Olson AL, Lai SY, Shete S, Harbison K, Scheid J, Jankowski M, Tanco KC. Utilization and dispensing patterns of medical cannabis products in a state with legalized medical cannabis. Journal of Clinical Oncology 41(16):e18844. PMID: None.
63. Popat UR, Lontos K, Bassett RL, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, MArin D, Mehta RS, Nieto Y, Oran B, Olson AL, Qazilbash MH, Ramdial JL, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules. Journal of Clinical Oncology 41(16):e7051. PMID: None.

Book Chapters

1. Rafei, H, Mehta, RS, Oran, B, Rezvani, K, Shpall, E, Olson, AL. Umbilical Cord Blood Transplantation, 101-114, 2023.
2. Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
3. P Kim P, L Masha L, A Olson A, C Iliescu C, K Karimzad K, S Hassan S, N Palaskas N, J Durand J, C Leung C, J Lopez-Mattei J. QT Prolongation in Cancer Patients. In: Frontiers in Cardiovascular Medicine: Re-Balancing The Balance: Another Story of Cardio-Oncology. None. Frontiers, 21-27, 2021.
4. Khan, M, Siddiqi, R, Shpall, E, Olson, AL. Principles and applications of cellular therapy in the setting of hematopoietic cell transplant. In: Hematopoietic Cell Transplantation for Malignant Conditions. Elsevier, 395-416, 2019.
5. Mehta, RS, Olson, AL, Ponce, DM, Shpall, E. Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. In: Hematology. 7. Elsevier, 1633-1649.e4, 2018.
6. Olson, AL, Shpall, E. Chapter 11: Cord blood cells for clinical use: expansion and manipulation. In: Cord Blood Stem Cells and Regenerative Medicine. Academic Press, 141-152, 2015.
7. Olson AL. Allogeneic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Chronic Myelogenous Leukemia. In: PocketOncology. None. Lippincott Williams and Wilkins Publishers, 2014.

Letters to the Editor

1. Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.